Aardvark Therapeutics Shares Plunge After Pausing Phase 3 HERO Clinical Trial

Key Facts

1Aardvark Therapeutics (AARD) shares fell during Monday's premarket session.

2The company announced a voluntary pause of its Phase 3 HERO trial for Prader-Willi Syndrome.

Shares of Aardvark Therapeutics (AARD) experienced a significant decline during Monday's premarket trading session. The sell-off followed the company's announcement of a voluntary pause in its Phase 3 HERO clinical trial. This pivotal trial was evaluating a potential treatment for Prader-Willi Syndrome, a rare genetic disorder. Investors reacted negatively to the news, as late-stage trial interruptions often signal potential safety concerns or efficacy hurdles. Such delays can significantly impact the drug's development timeline and the path toward regulatory approval. The company has not yet provided a specific timeline for when the trial might resume, leaving the market cautious about the stock's near-term outlook.